Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase II Study of Checkpoint Blockade Immunotherapy in Patients With Somatically Hypermutated Recurrent WHO Grade 4 Glioma

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT04145115
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-25T22:27:57.758359+00:00
Published At
2026-04-13T00:00:00+00:00
Record Updated At
2026-04-13
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Astrocytoma, IDH-Mutant, Grade 4", "Diffuse Glioma", "Glioblastoma, IDH-Wildtype", "Secondary Glioblastoma"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2026-04-13"
protocolSection.identificationModule.nctId
"NCT04145115"
protocolSection.identificationModule.officialTitle
"A Phase II Study of Checkpoint Blockade Immunotherapy in Patients With Somatically Hypermutated Recurrent WHO Grade 4 Glioma"
protocolSection.statusModule.overallStatus
"ACTIVE_NOT_RECRUITING"
protocolSection.designModule.phases
["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
""

Study condition terms

  • Astrocytoma, IDH-Mutant, Grade 4 (protocolSection.conditionsModule.conditions)
  • Diffuse Glioma (protocolSection.conditionsModule.conditions)
  • Glioblastoma, IDH-Wildtype (protocolSection.conditionsModule.conditions)
  • Secondary Glioblastoma (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.